Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€13.40

€13.40

0.600%
0.08
0.600%
-
 
13:09 / Tradegate WKN: A14UQC / Name: Abivax / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Abivax S.A. Stock

The Abivax S.A. stock is trending slightly upwards today, with an increase of €0.080 (0.600%) compared to yesterday's price.
For the coming years our community has positive and negative things to say abot the Abivax S.A. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Valuation (undervalued/overvalued)" there were negative voices in the community.

Pros and Cons of Abivax S.A. in the next few years

Pros
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
M***** P*******
Cons
?
S********** s********
?
W********* I********* f** t** n*** y****
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Abivax S.A. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Abivax S.A. 0.600% - - - - - -
Valneva SE 0.140% 4.236% 9.247% -24.117% -25.183% -65.626% 3.570%
Nanobiotix -0.540% 0.541% -6.689% 67.066% -13.084% -57.727% -48.854%
Transgene S.A. -0.550% -0.366% 7.937% -41.253% -18.806% -57.748% -61.281%

Comments

Prediction Buy
Perf. (%) 82.50%
Target price 6.970
Change
Ends at 14.09.16

(Zielkurs erreicht)
Show more

Prediction Buy
Perf. (%) 82.50%
Target price 6.970
Change
Ends at 14.09.16

DERFY stimmt der Outperform-Einschätzung der institutionellen Analysten zu

DERFY stimmt am 12.07.2016 der Outperform-Einschätzung der institutionellen Analysten mit dem Kursziel 26.97€ zu.
Show more

News

EQS-News: Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and sponsorship of scientific symposium at the 19th Congress of European Crohn’s and Colitis Organization (ECCO)
EQS-News: Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and sponsorship of scientific symposium at the 19th Congress of European Crohn’s and Colitis Organization (ECCO)
EQS-News: Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and sponsorship of scientific symposium at the 19th Congress of European Crohn’s and Colitis Organization (ECCO)
EQS-News: Abivax appoints Ana Sharma as Vice President, Global Head of Quality
EQS-News: Abivax appoints Ana Sharma as Vice President, Global Head of Quality
EQS-News: Abivax appoints Ana Sharma as Vice President, Global Head of Quality
EQS-News: Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease
EQS-News: Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease
EQS-News: Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease